A novel transflectance near infrared spectroscopy technique for monitoring hot melt extrusion by Kelly, Adrian L. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Available access to 
the published online version may require a subscription. 
Link to publisher’s version: http://dx.doi.org/10.1016/j.ijpharm.2015.07.025 
Citation:   Kelly AL, Halsey SA, Bottom RA, Korde S, Gough T and Paradkar A (2015) A novel 
transflectance near infrared spectroscopy technique for monitoring hot melt extrusion. 
International Journal of Pharmaceutics, 496 (1):117–123. 
Copyright statement: © 2015 Elsevier. Reproduced in accordance with the publisher's self-
archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 1 
 2 
A Novel Transflectance Near Infrared Spectroscopy Technique for Monitoring 3 
Hot Melt Extrusion 4 
 5 
A L Kelly
1*
, S A Halsey
2
, R A Bottom
2
, S Korde
1
, T Gough
1
, A Paradkar
1
 6 
 7 
 8 
1
 Centre for Pharmaceutical Engineering Science, University of Bradford BD7 1DP, UK 9 
2
 Thermo Fisher Scientific, Stafford House, Boundary Way, Hemel Hempstead HP2 7GE, 10 
UK 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
Corresponding Author:  27 
 28 
Dr Adrian Kelly 29 
Centre for Pharmaceutical Engineering Science, 30 
University of Bradford, Bradford, BD7 1DP, UK 31 
Tel: 00 44 1274 234532 32 
Email:  A.L.Kelly@Bradford.ac.uk  33 
 2 
ABSTRACT 34 
 35 
A transflectance near infra red (NIR) spectroscopy approach has been used to simultaneously 36 
measure drug and plasticiser content of polymer melts with varying opacity during hot melt 37 
extrusion. A high temperature reflectance NIR probe was mounted in the extruder die directly 38 
opposed to a highly reflective surface. Carbamazepine (CBZ) was used as a model drug, with 39 
polyvinyl pyrollidone-vinyl acetate co-polymer (PVP-VA) as a matrix and polyethylene 40 
glycol (PEG) as a plasticiser.  The opacity of the molten extrudate varied from transparent at 41 
low CBZ loading to opaque at high CBZ loading. Particulate amorphous API and voids 42 
formed around these particles were found to cause the opacity. The extrusion process was 43 
monitored in real time using transflectance NIR; calibration and validation runs were 44 
performed using a wide range of drug and plasticiser loadings.  Once calibrated, the 45 
technique was used to simultaneously track drug and plasticiser content during applied step 46 
changes in feedstock material. Rheological and thermal characterisations were used to help 47 
understand the morphology of extruded material. The study has shown that it is possible to 48 
use a single NIR spectroscopy technique to monitor opaque and transparent melts during 49 
HME, and to simultaneously monitor two distinct components within a formulation. 50 
 51 
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1. INTRODUCTION 60 
Hot Melt Extrusion (HME) is a continuous melt mixing process which can be used to 61 
generate amorphous drug forms in order to improve solubility. Typically, Active 62 
Pharmaceutical Ingredients (APIs) are dissolved or dispersed within a soluble polymer matrix 63 
(Crowley et al., 2007). Such approaches can be used to improve or control drug release and 64 
inhibit drug recrystallisation (Qi et al., 2008). HME generally refers to twin screw extrusion, 65 
which is a highly efficient mixing process whereby the polymer and additives are gradually 66 
melted by the action of rotating screws and heat transferred through the extruder barrel.  67 
Typically HME renders the drug amorphous, a state which can significantly enhance both 68 
drug solubility and bioavailability. The use of HME for manufacture of pharmaceuticals has 69 
been widely reported including applications such as pellets (Follonier et al., 1994), sustained 70 
release tablets (Tran et al., 2011; Crowley et al., 2004), implants (Bhardwaj and Blanchard, 71 
1997) and transdermal films (Aitken-Nichol et al., 1996).  A number of comprehensive 72 
reviews of the pharmaceutical HME process are available (Crowley et al., 2007; Repka et al., 73 
2007; Repka et al., 2012).  74 
During HME the API, polymer and other excipients are conveyed through a heated barrel by 75 
two closely intermeshing screws. The temperatures, mixing intensity and residence time to 76 
which the materials are subjected during the process can be varied by adjusting parameters 77 
such as set temperature, throughput, screw rotation speed and extruder screw configuration. 78 
Within the process the API and carriers experience high temperatures and levels of shear, 79 
which serve to melt the polymer and dissolve or disperse the API within the matrix. 80 
However, these harsh conditions can have adverse affects on many APIs, particularly those 81 
with thermolabile properties. Careful choice of excipients and optimisation of processing 82 
conditions are necessary in order to avoid degradation and produce a compound with the 83 
desired morphology and properties. 84 
HME has the advantage of being a continuous process which means that following an initial 85 
start up and stabilisation period, a consistent output can be maintained indefinitely, providing 86 
that the input feed of materials is correctly maintained.  Continuous processes are also well 87 
suited to in-line monitoring, or Process Analytical Technology (PAT).  The FDA now 88 
encourages process innovation in the pharmaceutical industry through better process 89 
understanding achieved by adopting Quality by Design (QbD) and PAT (FDA Guidance for 90 
Industry, 2004).  A range of techniques have been employed to monitor hot melt extrusion, 91 
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with spectroscopic measurements using high temperature probes most widely used (Saerens 92 
et al., 2013). Raman and near infra-red (NIR) spectroscopy techniques can provide qualitative 93 
and quantitative information about chemical and physical properties (De Beer et al., 2010). 94 
NIR spectroscopy is a rapid, non-destructive technique which refers to study of light 95 
absorption in the NIR region between 700-2500 nm and can be applied to the HME process 96 
(Wahl et al., 2013; Luypaert et al., 2007).  The technique has been used to study melt 97 
extrusion of metoprolol tartrate at different loadings in a polyvinyl pyrollidone – polyvinyl 98 
acetate copolymer (Saerens et al., 2012). Results demonstrated that NIR could be used to 99 
monitor API concentration and polymer-drug inter-molecular interactions. NIR has also been 100 
successfully used to monitor extrusion co-crystallisation (Kelly et al., 2012; Moradiya et al., 101 
2014a; Moradiya et al., 2014b). The use of Raman spectroscopy as a PAT tool for melt 102 
extrusion has also been reported, during extrusion of metoprolol tartrate and Eudragit, a 103 
commercial acrylic copolymer (Saerens et al., 2011). Raman and NIR spectroscopy have 104 
been used as complementary techniques to during HME of metoprolol tartrate with blends of 105 
polyethylene oxide and ethylene vinyl acetate (Almeida et al., 2012). Analysis of the 106 
spectroscopic data provided an improved understanding of the effects of process settings on 107 
the solid state of the API.   108 
A limitation of NIR spectroscopy in HME applications is that molten API/polymer systems 109 
can exhibit varying levels of reflectivity. Extrudates may range between clear and opaque 110 
depending upon API concentration and set temperature. In such cases a single design of 111 
probe type, reflectance or transmission, may not be used to collect spectra for all melt types. 112 
Reflectance probes can only gather spectra from cloudy or opaque melts and transmission 113 
probes are only suitable for clear melts. The aim of the current work was to apply a novel 114 
transflectance measurement technique to characterise a range of melts with varying levels of 115 
reflectivity. The design of the measurement system is described and a case study used to 116 
demonstrate the application of the technique to simultaneously measure two components 117 
during HME. 118 
 119 
2. MATERIALS AND METHODS 120 
2.1 Materials 121 
Carbamazepine (CBZ) was used as a model API, procured from Jai Radhe Sales India. This 122 
is an anticonvulsant and mood stabilising drug which has a molecular weight of 236 g/mol 123 
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and a melting temperature of 190°C.  Polyvinyl pyrrolidone-vinyl acetate (PVP-VA) 124 
copolymer (Kollidon® VA 64) was used as a matrix polymer, supplied by BASF, Germany.  125 
This has a molecular weight of 45,000 – 70,000 g/mol, a glass transition temperature (Tg) of 126 
101°C and a degradation temperature of 230°C. Polyethylene glycol (PEG) PEG2000 was 127 
used as a plasticiser, procured from Sigma Aldrich.  This had a molecular weight of 2000 128 
g/mol and a melting point of 50-53°C and was used to lower the viscosity of the materials to 129 
facilitate extrusion. PEG was introduced into the formulation to enable melt extrusion at a 130 
suitable temperature; CBZ alone added to PVP-VA was not found to provide sufficient levels 131 
of plasticisation. Physical mixtures of polymer, API and plasticiser were accurately weighed 132 
and mixed in a mortar and pestle prior to extrusion. 133 
2.2 Methods 134 
2.2.1 Hot Melt Extrusion 135 
Extrusion was performed using a co-rotating twin screw pharmaceutical grade extruder 136 
(Pharmalab, Thermo Scientific, UK) with screw diameter 16mm and a screw length to 137 
diameter ratio of 40:1. The extruder barrel comprised 10 separately temperature controlled 138 
zones. Material feeding was achieved using a gravimetric twin screw feeder (Mini-twin, 139 
Brabender, Germany). A slit die was designed to fit onto the front of the extruder, housing 140 
two sensor probes, located directly opposite each other across the melt flow, across a 1mm 141 
gap (Figure 1).  The transflectance measurement geometry comprised a high temperature 142 
reflectance NIR probe located in one port of the extruder die, and a stainless steel ‘blank’ 143 
sensor bolt with a polished tip located directly opposite the reflectance probe.  This set up 144 
was designed such that opaque melts could be measured directly using the conventional 145 
reflectance probe whereas for transparent melts light passing through the melt would be 146 
reflected from the polished surface and be collected by the reflectance probe.  Photographs of 147 
extrudates produced with different levels of CBZ and PEG are shown in Figure 2.  148 
Physical mixtures of CBZ, PVP-VA and PEG were prepared by manually mixing the 149 
constituents between the ranges of 5.0 - 27.5 weight % CBZ and 5.0 – 20.0 weight % PEG, 150 
with the remainder of each composition being made up of PVP-VA.  All extrusion 151 
experiments were performed at the same set temperatures, with temperature being profiled 152 
from 40°C at the feed end to 120°C at the extruder die as shown in table 1. Temperatures 153 
were selected following a series of initial extrusion trials at different set temperatures. The 154 
optimum set condition provided a good consistency of extrudate to be handled, whilst 155 
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generating a reasonable level of torque in the extruder drive.  Blended physical mixtures were 156 
fed into the extruder at 360 g/hr and the extruder was operated at a screw rotation speed of 50 157 
rpm. 158 
 159 
2.2.2 Near Infrared Spectroscopy 160 
NIR spectroscopy was performed using an Antaris II FT-NIR spectrometer (Thermo 161 
Scientific, UK). Off-line powdered ingredients were placed in clear glass vials and measured 162 
in reflectance mode using an integrating sphere. In-line measurements were made with a high 163 
temperature reflectance probe connected to the spectrometer using a fibre optic bundle. This 164 
probe was mounted in the extruder die as described above. For both off-line and in-line 165 
measurements, each sample reading averaged 32 individual spectra at a resolution of 8 cm
−1
, 166 
scanned over the region of 4,000–10,000 cm−1. The Thermo Scientific RESULT software 167 
was used to collect spectra. Off-line powder measurements were recorded singly and the in-168 
line measurements were recorded continuously at the exit die. Data collection time was 169 
approximately 30 seconds per spectrum. Measured spectra were then stored for subsequent 170 
analysis with Thermo Scientific TQ Analyst software. 171 
 172 
For each extrusion experiment, NIR spectra were collected in real time until the spectra were 173 
observed to stabilise.  For the experimental conditions used, this took approximately 15-20 174 
minutes.  NIR spectra at stable conditions were then collected for a period of around 10 175 
minutes before a new blend was introduced into the feeder and the process repeated.  An 176 
experimental design was used to minimise the correlation, 0.14, between the components. In-177 
line measurements on nineteen mixtures were used as a calibration set and four mixtures were 178 
analysed as validation samples.    179 
2.2.3 Rheological Characterisation  180 
Off-line rheological characterisation was carried out using a Physica MCR 501 rotational 181 
rheometer (Anton Paar, Austria) with parallel plate geometry of diameter 25mm. The gap 182 
between the two plates was set to 1 mm for all tests. Frequency sweeps were performed at a 183 
set temperature of 140°C and a constant strain of 3%; this value having been determined to 184 
be within the linear viscoelastic range by preceding strain amplitude tests. The angular 185 
frequency range tested was 0.1 - 100 s
-1
. Samples were prepared by mixing the desired ratio 186 
of drug, polymer and plasticiser in a mortar and pestle before placing the powdered mixture 187 
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on to the heated lower plate of the rheometer. Approximately one minute was allowed for the 188 
material to soften prior to the upper plate being lowered to the desired gap width of 1mm and 189 
any excess material was removed. The effect of CBZ and PEG on the viscosity of the 190 
compound was quantified by examining physical mixtures containing a range of CBZ 191 
loadings between 7.5 and 20 wt% (with PEG fixed at 10 wt%) and a range of PEG loadings 192 
from 2.5 – 15 wt% (with CBZ fixed at 10 wt%). 193 
2.2.4 Scanning Electron Microscopy (SEM) 194 
Extruded samples were mounted on aluminium pin-stubs (Agar Scientific, Stansted, U.K.) 195 
using self adhesive carbon mounts (Agar Scientific). The mounted samples were examined 196 
using FEI Quanta 400 Scanning Electron Microscope (Cambridge, U.K.) in high vacuum 197 
operated at an acceleration voltage of 20 kV. 198 
2.2.5 X-ray powder diffraction (XRPD) 199 
The crystallinity of milled samples of extrudate and pure API were assessed by X-ray powder 200 
diffraction (XRPD) within 24 hours of extrusion, using a Bruker D8 diffractometer 201 
(wavelength of X-rays 0.154 nm Cu source, voltage 40 kV, and filament emission 40 mA). 202 
Samples were scanned from 2 to 30° (2θ) using a 0.01° step width and a 1 s time count. The 203 
receiving slit was 1° and the scatter slit was 0.2°. 204 
 205 
3. RESULTS AND DISCUSSION 206 
3.1 Rheological Characterisation 207 
Complex viscosity of physical mixtures containing varying levels of CBZ and PEG are 208 
displayed in Figure 3. PEG had a significant effect on melt viscosity over the range 209 
examined, with complex viscosity decreasing from 500 Pa.s at 2.5% PEG loading to 65 Pa.s 210 
at 15% PEG content.  CBZ was observed to have a much less significant effect on melt 211 
viscosity, causing a relatively small decrease of 10% between 7.5 and 20% loading. These 212 
differences in flow behaviour were apparent during the extrusion experiments, as evidenced 213 
by extruder motor torque measurements shown in Figure 4.  Motor torque reflects the levels 214 
of energy required to turn the extruder screws at the set rotation speed; these measurements 215 
were found to closely reflect the viscosity results show in Figure 3. 216 
 217 
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3.2 Structural Characterisation  218 
X-ray diffractograms of extruded materials are compared to those of carbamazepine in 219 
figures 5a and 5b.  The crystalline peaks evident in CBZ were not observed in any of the 220 
extruded compounds, even at a CBZ loading of 30 wt%.  These results demonstrate that the 221 
crystalline CBZ was converted to an amorphous form during extrusion. 222 
3.3. Morphological Characterisation 223 
Scanning electron microscopy was performed on surfaces of extrudates in an attempt to 224 
understand the opaque nature of compounds with higher CBZ loadings. Figure 6 shows 225 
results from the fractured cross section (a) and outer surface (b) of an extruded strand 226 
containing 30% CBZ and 10% PEG.  The polymer matrix (PVP-VA) being amorphous in 227 
nature is predominantly transparent. However, the presence of particulates with diameters in 228 
the range of 10-30 microns and a number of voids or bubbles are evident from these images.  229 
It is thought that amorphous particulates of API were formed during extrusion which led in 230 
some cases to voids forming around the particles. Due to the high melting temperature of the 231 
API (190 °C) a solid solution could not be formed during extrusion at higher API loadings. 232 
These particulates and voids explain the opaque appearance of the extrudates. 233 
3.4. Near Infra-red spectroscopy  234 
NIR spectra of the powdered feedstock materials were measured to determine the peaks of 235 
interest for both the CBZ and PEG, as shown in Figure 7. NIR spectra are typically broad and 236 
overlapping and are usually enhanced with a derivative mathematical treatment. A second 237 
derivative treatment was applied to these spectra, as shown in Figure 8.  Strong and unique 238 
peaks could be seen for CBZ, but the PEG peaks were weaker and tended to overlap with the 239 
other two components. The 5600-6000 cm
-1
 region showed the most promise for the PEG 240 
measurement. For this reason, partial least squares (PLS) was selected for the regression 241 
method as this has been shown to have the ability to extract information from convoluted 242 
peaks (Faber and Kowalski, 1977). 243 
Figure 9 shows the NIR spectra of some selected samples collected at the extruder exit die; 244 
the samples ranged from clear to opaque. It should be noted that the 4500-4000 cm
-1
 region 245 
was noisy due to energy losses along the fibre optic bundle. This region was left out of the 246 
calculations during method development. This figure also shows that the baseline of the 247 
spectra changed quite considerably with different sample compositions. This was due to the 248 
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samples having different scattering properties as samples varied widely in cloudiness. 249 
However, the use of the transflectance measurement technique allowed data to be collected 250 
for all sample types. During method development a derivative mathematical treatment 251 
minimised the effect of the change in baseline on the final measurements.  The region chosen 252 
for regression was 6208-4754 cm
-1
 which incorporated peaks from both CBZ and PEG. 253 
Figure 10 shows the change in the second derivative spectra for the CBZ concentration when 254 
the PEG was held constant. Several peaks were seen to increase in accordance with the CBZ 255 
concentration, the peak at 5064 cm
-1
 being particularly strong.  Figure 11 shows the change in 256 
second derivative spectra for the PEG concentration when the CBZ was held constant. The 257 
5600-6000 cm
-1
 region did exhibit some changes, but the PEG peaks were masked by the 258 
other components. 259 
In-line measurements were used to calibrate the NIR instrument. Three or four spectra were 260 
used from each extrudate and the samples were split into calibration (66 samples) and 261 
validation (12 samples) sets. The results from the PLS regression are shown in Figure 12. 262 
Correlation coefficients of >0.99 were achieved between the NIR results and the weight data 263 
for CBZ measurements. Four factors were used for the CBZ calibration which gave good 264 
calibration (RMSEC) and validation (RMSEP) errors of 0.788% and 0.672% respectively. 265 
The PEG calibration was slightly less accurate with a calibration error of 0.633% and a 266 
validation error of 1.06%. The correlation coefficients dropped to 0.986 and 0.967 267 
respectively. Six factors were required to achieve this calibration which was expected 268 
considering the PEG peaks were much less prominent than those for CBZ. 269 
These calibrations were then used to monitor an extrudate in real time for both CBZ and PEG 270 
concentrations. A step change in the content of feedstock material was applied and calibrated 271 
NIR signals used to dynamically track these changes at the extruder die.  CBZ level was 272 
changed from 22.5% to 16% and PEG loading from 9% to 11%. The concentrations of both 273 
components were measured simultaneously and plotted against time, as shown in Figure 13. 274 
A smooth transition can be seen from the two original concentrations to the two new 275 
concentrations; demonstrating that these measurements could be used for routine quality 276 
control of an extrudate. In addition, this data showed that it took approximately 15 minutes 277 
for the new batch of material to fully flush the previous sample through the extruder under 278 
these process conditions.  However, it should be noted that these experiments were performed 279 
at relatively low throughput and screw rotation speed. Typical residence times in production 280 
are likely to be significantly lower. 281 
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 282 
4. CONCLUSIONS 283 
A transflectance FT-NIR spectroscopy technique was developed for monitoring the hot melt 284 
extrusion process.  A slit die was designed which enabled a reflectance NIR probe to be 285 
mounted directly opposite a highly polished surface, enabling measurements to be performed 286 
in both transmittance and reflectance modes.  The technique was successfully applied to 287 
extrusion of carbamazepine in a polyvinyl pyrrolidone-vinyl acetate copolymer matrix with 288 
polyethylene glycol used as a plasticiser.  At low API content the melt was transparent 289 
whereas at higher loadings it became opaque due to the presence of particulate API and voids 290 
which formed around these particles.  Calibration of the NIR technique was performed using 291 
a wide range of API and plasticiser loadings. The calibrated technique was used to 292 
simultaneously monitor the loading of both API and plasticiser in real time, across 293 
transparent and opaque melt regions. 294 
 295 
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 367 
Table I: Temperature profiles across the different zones of the extruder barrel (°C) 368 
 369 
 370 
 371 
Table II: Formulation of batches used for PLS model calibration 372 
 373 
CBZ (%) PEG (%) PVP-VA (%) 
5 10 85 
6 14 80 
7.5 12.5 80 
8 7 85 
10 10 80 
11 13 76 
12.5 7.5 80 
15 10 75 
14 8 78 
18 12 70 
20 10 70 
20 5 75 
20 15 65 
20 20 60 
20 7.5 72.5 
21 18 61 
25 10 65 
27.5 17.5 55 
30 10 60 
 374 
 375 
Table III: Formulation of batches used for PLS model validation 376 
 377 
CBZ (%) PEG (%) PVP-VA (%) 
9 16 75 
16 11 73 
22.5 9 68.5 
24 19 57 
 378 
Zone 10 Zone 9 Zone 8 Zone 7 Zone 6 Zone 5 Zone 4 Zone 3 Zone 2 Zone 1 
120 120 120 120 120 120 120 70 50 40 
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a) Model showing sensor location related 
to flowpath 
b) Photograph of die during extrusion 
Figure 1  Pharmalab extruder die designed to accommodate two opposing sensor ports across 379 
a 1mm flow path 380 
 381 
 
(a) 5, 15, 30% CBZ at 10% PEG 
 
(b) 5, 15, 20% PEG at 20% CBZ 
Figure 2  HME extrudate showing variation in opacity 
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 383 
Figure 3 Complex viscosity of physical mixtures measured at 1s
-1
 showing the effect of 384 
carbamazepine and PEG loading 385 
 386 
 387 
 388 
 389 
Figure 4 Measured extruder motor torque showing the effect of carbamazepine and PEG 390 
loading 391 
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 394 
Figure 5a PXRD results showing the effect of CBZ content 395 
 396 
 397 
 398 
Figure 5b PXRD results showing the effect of PEG content 399 
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 402 
 403 
 
(a) 
 
(b) 
 404 
Figure 6 SEM images of extrudate surfaces for 30% CBZ, 10% PEG;  405 
a) fracture surface, b) top surface of extrudate  406 
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 407 
Fig. 7 Off-line FT-NIR spectra of pure components 408 
 409 
 410 
 411 
Fig. 8 Off-line second derivative spectra of pure components 412 
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 414 
Fig. 9 In-line FT-NIR spectra of extrudates at the die exit 415 
 416 
 417 
 418 
Fig. 10 In-line second derivative spectra extrudates showing CBZ concentration changes, 419 
PEG held constant at 10% by weight 420 
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 422 
 423 
Fig. 11 In-line second derivative spectra extrudates showing PEG concentration changes, 424 
CBZ held constant at 20% by weight 425 
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 428 
Fig. 12a PLS regression results for CBZ 429 
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 431 
 432 
Fig. 12b PLS regression results for PEG 433 
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 436 
 437 
 438 
Fig. 13 Plot of CBZ and PEG concentrations measured in real time following an imposed step 439 
change in feedstock from 22.5% to 16% CBZ and 9% to 11% PEG 440 
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